About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
CLL and Therapy Related Myeloid Neoplasia in Chemoimmunotherapy Era: Norway Data
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Andrea Lenartova
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Andrea Lenartova
9 views
October 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Chronic Lymphocytic Leukemia
13:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Shifting Standard of Care for Frontline Therapy of CLL: Which Patien…
Feat.
N. Jain
11:37
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CLL State of the Art Update: Ibrutinib Prolongs PFS Compared to CIT,…
Feat.
J. Brown
15:20
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Discussion on the Next Generation Small Molecules in CLL: 2nd Genera…
Feat.
J. Woyach
05:46
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
62 y/o Male Diagnosed With CLL, Treated w/Mono Retuximab, Differenti…
Feat.
A. Ferrajoli
04:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
72 y/o Female w/Relapsed Rai Stage IV CLL Treated w/Ibrutinib and Ri…
Feat.
A. Ferrajoli
06:07
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
63 y/o Male w/Untreated CLL Rai I, Acute Hepatitis and Fever Work-Up…
Feat.
A. Ferrajoli
13:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CAR-T Cell Therapy in Chronic Lymphocytic Leukemia (CLL): Manageable…
Feat.
T. Siddiqi
16:05
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Reassessing Prognostic Markers (IGHV, TP53, CD49d, and B2M) in the E…
Feat.
A. Wiestner
06:23
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive an…
Feat.
J. Woyach
07:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CLL and Therapy Related Myeloid Neoplasia in Chemoimmunotherapy Era:…
Feat.
A. Lenartova